Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV-0400
- Development stage
- Preclinical
- Lead developer
- Sauvie BiKE
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
SV-0400 is a preclinical-stage multi-specific antibody developed by Sauvie Inc. using its proprietary CAM-V™ (Constant domain of Antibody Mimicry and Variation) platform. It is designed as a bispecific killer cell engager (BiKE) that simultaneously targets CD16a (an activating receptor on natural killer cells and other immune effectors) and HER2 (human epidermal growth factor receptor 2) on tumor cells. By bridging these two targets, SV-0400 facilitates the recognition, activation, and lysis of HER2-positive cancer cells through antibody-dependent cellular cytotoxicity (ADCC). The construct, composed of VHH nanobody domains, was originally developed at Rutgers University and is currently being optimized for the treatment of HER2-positive cancers.
- Other names
- SV-0400-Sauvie-CD16a-HER2-CAM-V antibodySV0400-Sauvie-CD16a-HER2-CAM-V antibodySV 0400-Sauvie-CD16a-HER2-CAM-V antibodyCAM-V HER2 antibody
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SV-0400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV-0400.